Composite solution of PEG-PLA copolymer as well as preparation method and application of composite solution

Through the combination of PEG-PLA copolymer and hyaluronate, the aggregation and cytotoxicity of polylevolate microspheres during the injection process are solved, the safety and anti-oxidation properties of the injection are improved, and the anti-aging and anti-aging of the skin is achieved. Brighten skin tone effect.

CN119055555APending Publication Date: 2024-12-03MEIYAN SPACE (HEBEI) BIOTECHNOLOGY CO LTD +1

Patent Information

Application Number
CN202410577249.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-10
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing polylevolactate microspheres are prone to aggregation, plug needles, displace, and cause subcutaneous tissue nodules during injection. The polyethylene glycol-polylevolactate copolymer is cytotoxic and has poor safety in use.

Method used

A composite solution of PEG-PLA copolymer was prepared, and the PEG-PLA copolymer was combined with hyaluronate through polymerization to form a uniformly distributed composite solution, improving injection and cytotoxicity and increasing antioxidant properties.

Benefits of technology

It solves the aggregation and cytotoxicity of polylevolate microspheres, improves the safety and antioxidant properties of injection, promotes the production of hydroxyproline and hyaluronic acid in the skin, and has significant anti-aging and brightens the skin tone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055555A_ABST
    Figure CN119055555A_ABST
Patent Text Reader

Abstract

The invention discloses a composite solution of a PEG-PLA copolymer as well as a preparation method and application of the composite solution. The composite solution of the PEG-PLA copolymer is prepared from the following components in parts by weight: 2 to 15 parts of PEG-PLA copolymer and 0.05 to 0.8 part of hyaluronate; preferably, the composite solution of the PEG-PLA copolymer comprises a buffer solution. The composite solution of the PEG-PLA copolymer has no precipitate, has good needle passing performance, and is not easy to cause displacement aggregation and nodules after injection. The two components in the composite solution of the PEG-PLA copolymer have a synergistic promotion effect, and compared with a single component, the cytotoxicity is reduced, the use safety is improved, and the oxidation resistance is improved. The PEG-PLA copolymer has a protective effect on the hyaluronate, and the oxidative degradation degree of the hyaluronate is reduced. The composite solution of the PEG-PLA copolymer shows more excellent anti-aging, skin color brightening and spot fading effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical cosmetology, and specifically relates to a composite solution of a PEG-PLA copolymer and a preparation method and application thereof. Background Art

[0002] In the biomedical field, lactic acid is a widely studied material. There is clear evidence that lactic acid has the function of promoting collagen production. Therefore, materials containing lactic acid can be used in medical beauty to fill relevant parts and stimulate collagen production. Related products have also been launched on the market, the most representative of which is poly-L-lactic acid (PLLA). Poly-L-lactic acid can slowly degrade into lactic acid in a physiological environment, thereby realizing the function of lactic acid.

[0003] Poly-L-lactic acid is a type of lipophilic polymer material. Although it has very high biosafety, due to its hydrophobic properties, it is usually prepared into micron-sized particles or microspheres during the process of filling parts in the human body. Due to problems such as inappropriate size and poor dispersion in the aqueous phase, the microspheres are prone to aggregation during the injection process, which in turn leads to needle blockage, increasing the difficulty of the doctor's operation and the pain of the patient. Granular poly-L-lactic acid is also prone to displacement and aggregation after being injected into the human subcutaneous tissue, which can easily cause nodules in the subcutaneous tissue, causing certain clinical safety risks.

[0004] Polyethylene glycol (PEG) has become a widely used hydrophilic block due to its good hydrophilicity and biocompatibility, and can avoid being recognized and captured by organs such as the reticuloendothelial system (RES), liver, spleen, and kidney in the body, and has a long blood circulation time. The Chinese patent application with application number 202211405926.X provides a polyethylene glycol-poly (L-lactic acid) copolymer, which has both hydrophilic and hydrophobic segments, and has no peptide chains on the molecule, no immunogenicity, and is easily biodegraded into metabolites in the body, and is easily excreted from the body without accumulation. However, the inventors found during the research process that the polyethylene glycol-poly (L-lactic acid) copolymer has greater cytotoxicity when used alone and has poor safety of use.

[0005] Therefore, there is an urgent need in this field to develop a medical beauty material that is highly safe to use, has a sustained release of lactic acid, and can fully exert its beauty effects. Summary of the invention

[0006] The technical problem to be solved in this application is to overcome the poor hydrophilicity of poly-L-lactic acid in the prior art, and the poly-L-lactic acid microspheres are prone to aggregation, needle blocking, obvious pain, displacement, redness, swelling and nodule formation and other adverse reactions after injection; the polyethylene glycol-poly-L-lactic acid copolymer has high cytotoxicity and poor safety in use, and a composite solution of a PEG-PLA copolymer and its preparation method and application are provided. In the composite solution of the PEG-PLA copolymer prepared in this application, the PEG-PLA copolymer is evenly distributed, has no precipitation, has good needle permeability, and is not easy to cause problems such as displacement aggregation and nodules after injection. In the composite solution of the PEG-PLA copolymer, the two components have a synergistic promotion effect, and compared with a single component, the cytotoxicity is significantly reduced, the safety of use is improved, and the antioxidant performance is improved. The PEG-PLA copolymer also has a protective effect on hyaluronate, reducing the degree of oxidative degradation of hyaluronate. The composite solution of PEG-PLA copolymer can induce the skin to produce more hydroxyproline and hyaluronic acid, showing a more excellent anti-aging effect; it can also reduce the content of lipofuscin in the skin, and has the effects of brightening the skin tone and lightening spots. The composite solution of PEG-PLA copolymer in the present application has a simple preparation process, mild reaction conditions, short production cycle, lower cost, and is easy to industrialize.

[0007] This application solves the above technical problems through the following technical solutions.

[0008] The present application provides a composite solution of a PEG-PLA copolymer, wherein the composite solution of the PEG-PLA copolymer comprises the following components in parts by weight: 2 to 15 parts of a PEG-PLA copolymer and 0.05 to 0.8 parts of a hyaluronate; preferably, the composite solution of the PEG-PLA copolymer comprises a buffer solution.

[0009] In some embodiments, the weight proportion of the PEG-PLA copolymer is 2 to 12 parts, preferably 2 to 10 parts, more preferably 2 to 6 parts, such as 3 to 5 parts or 3 to 4 parts.

[0010] In some embodiments, the weight portion of the hyaluronate is 0.05 to 0.6 parts, preferably 0.1 to 0.5 parts.

[0011] In some embodiments, the pH value of the composite solution of the PEG-PLA copolymer is 4-7.5, preferably 5-7, and more preferably 5.5-6.5.

[0012] In some embodiments, the osmotic pressure of the composite solution of the PEG-PLA copolymer is 200 mOsmol / kg to 400 mOsmol / kg, preferably 250 mOsmol / kg to 350 mOsmol / kg.

[0013] In some embodiments, the composite solution of the PEG-PLA copolymer includes the PEG-PLA copolymer, the hyaluronate and the buffer; wherein the mass percentage of the PEG-PLA copolymer in the composite solution of the PEG-PLA copolymer is 2% to 15%; the mass percentage of the hyaluronate in the composite solution of the PEG-PLA copolymer is 0.05% to 0.8%.

[0014] In a preferred embodiment, the mass percentage of the PEG-PLA copolymer in the composite solution of the PEG-PLA copolymer is 2% to 12%, more preferably 2% to 10%, further more preferably 2% to 6%, for example 3% to 5% or 3% to 4%.

[0015] In a preferred embodiment, the mass percentage of the hyaluronate in the composite solution of the PEG-PLA copolymer is 0.05% to 0.6%, more preferably 0.1% to 0.5%, such as 0.2%, 0.3% or 0.4%.

[0016] In some embodiments, the preparation method of the PEG-PLA copolymer comprises the following steps: preparing the PEG-PLA copolymer by polymerization reaction of a single-terminal hydroxyl polyethylene glycol compound and lactide.

[0017] The mass ratio of the single-end hydroxyl polyethylene glycol compound to the lactide is (3.5-49):1, preferably (9-49):1, preferably (9-20):1, for example 9:1 or 19:1.

[0018] Wherein, the single-terminal hydroxyl polyethylene glycol compound is polyethylene glycol monoalkyl ether, preferably polyethylene glycol mono C 1-6 The alkyl ether is more preferably polyethylene glycol monomethyl ether.

[0019] The weight average molecular weight of the single-end hydroxyl polyethylene glycol compound is 1000-11000 Da, preferably 4000-11000 Da, more preferably 5000-10000 Da, such as 1000 Da, 2000 Da, 4000 Da, 5000 Da or 10000 Da.

[0020] Wherein, the lactide is selected from at least one of L-lactide, D-lactide and D,L-lactide.

[0021] Wherein, the polymerization reaction is carried out under the action of a catalyst.

[0022] Preferably, the catalyst is a tin-based metal catalyst, more preferably at least one selected from dibutyltin diacetate, dibutyltin dibenzoate, tri-n-butyltin methoxylate, dibutyltin dilaurate, stannous octoate, stannous octoate and stannous isooctanoate.

[0023] Preferably, the mass percentage of the catalyst in the polymerization reaction system is 0.01% to 0.03%, preferably 0.02% to 0.03%.

[0024] The polymerization reaction can be carried out under anaerobic conditions according to the conventional art. According to the conventional art, the system can be controlled to reach anaerobic conditions by vacuuming and / or filling with an inert atmosphere.

[0025] Preferably, when the vacuuming method is adopted, the vacuuming time may be conventional in the art, generally 20 to 50 minutes, preferably 25 to 35 minutes, for example 25 minutes.

[0026] Preferably, the inert atmosphere is selected from nitrogen and / or inert gases conventionally used in the art.

[0027] Wherein, the polymerization reaction is a melt polymerization reaction.

[0028] The polymerization reaction temperature is 70-150°C, preferably 90-135°C, more preferably 100-130°C, such as 110°C.

[0029] The polymerization reaction time is 8 to 20 hours, preferably 11 to 16 hours, for example 12 hours.

[0030] Wherein, the polymerization reaction may further include purification and / or drying operations. The purpose of the purification is to remove unreacted single-terminal hydroxyl polyethylene glycol compound, lactide and catalyst.

[0031] Preferably, the purification comprises the following steps: the material after the polymerization reaction is mixed with a good solvent once, dissolved and then mixed with a poor solvent for a second time, crystallized, and the precipitate is collected.

[0032] During the purification process, the good solvent can be a solvent that is generally considered by those skilled in the art to be easily soluble in the PEG-PLA copolymer, preferably selected from halogenated alkanes, wherein the halogenated alkanes are selected from dichloromethane and / or chloroform.

[0033] During the purification process, the mass volume ratio of the material after the polymerization reaction to the good solvent is 0.8 to 3 g / mL, preferably 1 to 2 g / mL.

[0034] In the purification process, the first mixing may further include an adsorption operation. Preferably, the adsorbent used in the adsorption is selected from activated carbon. Preferably, the mass volume ratio of the adsorbent used in the adsorption to the adsorbed system is 75 to 150 g / L, for example, 100 g / L. More preferably, the adsorption operation may further include an operation of filtering to remove the adsorbent.

[0035] During the purification process, the poor solvent can be a solvent commonly used by those skilled in the art that does not easily dissolve the PEG-PLA copolymer, preferably an ether solvent, wherein the ether solvent is isopropyl ether and / or diethyl ether.

[0036] In the purification process, the volume ratio of the good solvent to the poor solvent is 1:(4-10), preferably 1:(6-10).

[0037] In the purification process, the method of collecting the precipitate includes filtration and / or centrifugation.

[0038] Preferably, the drying can be performed in an oven according to the conventional art.

[0039] Preferably, the drying temperature is 20-50°C, more preferably 30-40°C, more preferably 33-37°C, for example 35°C.

[0040] Preferably, the drying time is 12 to 48 hours, more preferably 20 to 48 hours, for example 24 hours.

[0041] In some embodiments, the hyaluronate is selected from at least one of sodium hyaluronate, potassium hyaluronate, calcium hyaluronate and zinc hyaluronate, preferably sodium hyaluronate.

[0042] In some embodiments, the weight average molecular weight of the hyaluronate is 8 WDa to 150 WDa, preferably 100 WDa to 140 WDa, for example 60 WDa to 120 WDa or 130 WDa.

[0043] In some embodiments, the buffer is selected from any one of phosphate buffer, citrate buffer, sodium chloride solution, EDTA-EDTA buffer and citric acid-citrate buffer or a combination thereof, preferably selected from at least one of phosphate-phosphate buffer, dihydrogen phosphate-dihydrogen phosphate buffer, citric acid-citrate buffer, EDTA-EDTA buffer and citric acid-citrate buffer.

[0044] In a preferred embodiment, the buffer is any one of sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate, or a combination thereof.

[0045] In some embodiments, the pH value of the buffer solution is 7-12, preferably 7-9.

[0046] In some embodiments, the osmotic pressure of the buffer solution is 120-410 mOsmol / kg, preferably 220-400 mOsmol / kg.

[0047] The present application also provides a method for preparing the composite solution of the PEG-PLA copolymer as described above, comprising the following steps: uniformly mixing the components in the composite solution of the PEG-PLA copolymer.

[0048] In some embodiments, the mixing operation may further include a sterilization operation.

[0049] Wherein, the sterilization method includes filtration and / or irradiation sterilization.

[0050] The present application also provides a composite solution of the PEG-PLA copolymer as described above for use as a raw material in the preparation of injectable preparations in the field of medical beauty.

[0051] In some embodiments, the injectable preparation is an injection solution or a lyophilized powder injection.

[0052] In some embodiments, the injection site of the injectable preparation is selected from any one of the face, neck, abdomen, chest, buttocks, thigh, calf, upper arm, lower arm, or a combination thereof.

[0053] In some embodiments, the injectable preparation is used to improve any one or a combination of facial emaciation, fat atrophy, sunken cheeks, sunken eye sockets, and skin wrinkles in a patient.

[0054] On the basis of conforming to the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present application.

[0055] The reagents and raw materials used in this application are commercially available.

[0056] The positive and progressive effects of the present application are: the present application compounds PEG-PLA copolymer and hyaluronate, and the PEG-PLA copolymer is evenly distributed in the solution, has good needle permeability, and is not easy to cause problems such as displacement aggregation and nodule formation after injection. The two components in the composite solution of PEG-PLA copolymer have a synergistic promotion effect. Compared with the single component, the cytotoxicity is significantly reduced, the safety of use is improved, and the antioxidant performance is also improved. The PEG-PLA copolymer also has a protective effect on hyaluronate, reducing the degree of oxidative degradation of hyaluronate. In addition, the composite solution of PEG-PLA copolymer can induce the skin to produce more hydroxyproline and hyaluronic acid, showing a more excellent anti-aging effect; it can also reduce the content of lipofuscin in the skin, and has the effects of brightening the skin color and lightening spots. The preparation process of the composite solution of PEG-PLA copolymer in the present application is simple, the reaction conditions are mild, the production cycle is short, the cost is lower, and it is easy to industrialize. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 is the H NMR spectrum of PEG-PLA copolymer 1;

[0058] Figure 2 is the infrared spectrum of PEG-PLA copolymer 1;

[0059] Figure 3 : is a comparison chart of lipofuscin (LF) content in the tested skin tissue after the composite solution of PEG-PLA copolymer prepared in Example 1 was injected into the back skin tissue of mice compared with the control group and the model group;

[0060] Figure 4 : This is a comparison chart of the hydroxyproline (HYP) content in the tested skin tissue after the composite solution of the PEG-PLA copolymer prepared in Example 1 was injected into the back skin tissue of mice compared with the control group and the model group;

[0061] Figure 5 1 is a comparison chart of hyaluronic acid (HA) content in the tested skin tissue after the composite solution of PEG-PLA copolymer prepared in Example 1 was injected into the back skin tissue of mice compared with the control group and the model group. DETAILED DESCRIPTION

[0062] The present application is further described below by way of examples, but the present application is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the product instructions.

[0063] The reagents and raw materials used in the following examples are all commercially available, and the purity of the reagents used is injection grade.

[0064] PEG-PLA copolymer 1

[0065] Weigh polyethylene glycol monomethyl ether (molecular weight 5000Da) and L-lactide in a ratio of 90:10, add the sample to a round-bottom flask, maintain an oil bath at 90°C, stir, and after the sample is completely melted, evacuate for about 30 minutes, then add stannous octoate as a catalyst, and continue to evacuate for about 30 minutes until no bubbles appear. The mass percentage of stannous octoate to the total amount of polyethylene glycol monomethyl ether and L-lactide is 0.02%. Adjust the temperature to 110°C, react for 12 hours, and obtain a crude PEG-PLA copolymer. Add dichloromethane to the crude PEG-PLA copolymer for oscillation and washing to remove unreacted monomers, then add excess dichloromethane, stir until the polymer is completely dissolved, the mass volume ratio of the crude PEG-PLA copolymer to dichloromethane is 1g / mL, and then add activated carbon (the mass volume ratio to the adsorbed system is 100g / L), continue stirring for 30 minutes, filter to remove the activated carbon, and the pore size of the filter membrane is 0.22μm. Add isopropyl ether to the product solution and stir thoroughly until the copolymer is completely precipitated. The volume ratio of dichloromethane to isopropyl ether is 1:6. Filter with suction and place the product in an oven at 35°C for about 24 hours to obtain PEG-PLA copolymer 1.

[0066] The structure of PEG-PLA copolymer 1 was analyzed. The hydrogen spectrum of PEG-PLA copolymer 1 was measured using a nuclear magnetic resonance spectrometer, and the solvent was CDCl3. The results are shown in Figure 1 The infrared spectrum of PEG-PLA copolymer 1 was measured by Fourier transform infrared spectrometer. Figure 2 The determination method is potassium bromide tablet method. The results of H NMR spectrum are consistent with the types and connection positions of hydrogen atoms contained in the target product. Hydrogen connected to the ester group at chemical shifts of 5.13-5.24 can be observed in the H NMR spectrum; strong absorption peaks of the carbon-oxygen double bond of the ester group can be observed in the infrared spectrum, indicating that methoxy polyethylene glycol and L-lactide undergo polymerization to produce ester groups, which is consistent with the structure of the target product.

[0067] PEG-PLA copolymer 2

[0068] Weigh polyethylene glycol monomethyl ether (molecular weight 10000Da) and L-lactide in a ratio of 90:10, add the sample to a round-bottom flask, maintain an oil bath at 90°C, stir, and after the sample is completely melted, evacuate for about 30 minutes, then add stannous octoate as a catalyst, the mass percentage of stannous octoate to the total amount of polyethylene glycol monomethyl ether and L-lactide is 0.02%, and continue to evacuate for about 30 minutes until no bubbles appear. Adjust the temperature to 110°C, react for 12 hours, and obtain a crude PEG-PLA copolymer. Add a small amount of dichloromethane to the crude PEG-PLA copolymer for oscillation and washing to remove unreacted monomers, then add excess dichloromethane and stir until the copolymer is completely dissolved, the mass volume ratio of the crude PEG-PLA copolymer to dichloromethane is 1g / mL, add activated carbon (the mass volume ratio to the adsorbed system is 100g / L), continue stirring for 30 minutes, filter to remove the activated carbon, and the pore size of the filter membrane is 0.22μm. Add isopropyl ether to the product solution, with the volume ratio of dichloromethane to isopropyl ether being 1:6, and stir thoroughly until the copolymer is completely precipitated. Filter with suction, and place the product in an oven at 35°C for about 24 hours to obtain PEG-PLA copolymer 2.

[0069] PEG-PLA copolymer 3

[0070] Weigh polyethylene glycol monomethyl ether (molecular weight 5000Da) and L-lactide in a ratio of 95:5, add the sample to a round-bottom flask, maintain an oil bath at 90°C, stir, and after the sample is completely melted, evacuate for about 30 minutes, then add stannous octoate as a catalyst, the mass percentage of stannous octoate to the total amount of polyethylene glycol monomethyl ether and L-lactide is 0.02%, and continue to evacuate for about 30 minutes until no bubbles appear. Adjust the temperature to 110°C, react for 12 hours, and obtain a crude PEG-PLA copolymer. Add a small amount of dichloromethane to the crude PEG-PLA copolymer for oscillation and washing to remove unreacted monomers, then add excess dichloromethane and stir until the copolymer is completely dissolved, the mass volume ratio of the crude PEG-PLA copolymer to dichloromethane is 1g / mL, add activated carbon (the mass volume ratio to the adsorbed system is 100g / L), continue stirring for 30 minutes, filter to remove the activated carbon, and the pore size of the filter membrane is 0.22μm. Add isopropyl ether to the product solution, with the volume ratio of dichloromethane to isopropyl ether being 1:6, and stir thoroughly until the copolymer is completely precipitated. Filter with suction, and place the product in an oven at 35°C for about 24 hours to obtain PEG-PLA copolymer 3.

[0071] Example 1 Preparation of PEG-PLA copolymer composite solution

[0072] The raw materials were mixed in a ratio of 1 mg / mL sodium hyaluronate (molecular weight 130 WDa) and 30 mg / mL PEG-PLA copolymer 1, and a phosphate buffer solution (0.2 mol / L disodium hydrogen phosphate dodecahydrate and 0.2 mol / L sodium dihydrogen phosphate dihydrate prepared in a ratio of 5:3, and the pH was adjusted to 7.0) to form a solution, which was filtered with 0.45 μm and 0.22 μm filter membranes to obtain a complex solution.

[0073] Examples 2-9 and Comparative Examples 1-5

[0074] Compared with Example 1, the only difference is the type of PEG-PLA copolymer and the concentration of each component. Other condition parameters are the same as Example 1. Please see Table 1 for details.

[0075] Table 1

[0076]

[0077] Note: “ / ” in Table 1 means that the component was not added.

[0078] Effect Example 1 Solubility Investigation

[0079] The composite solutions of the PEG-PLA copolymers prepared in the above-mentioned embodiments were observed and placed at room temperature for 48 hours. The states were observed. The results are shown in Table 2.

[0080] Table 2

[0081]

[0082] The above results show that each component in the composite solution of PEG-PLA copolymer prepared in the embodiment of the present application is completely dissolved, and the composite solution of PEG-PLA copolymer still has no precipitation after being placed for 48 hours. The system is stable, and needle blockage will not occur during use, which can reduce the difficulty of doctor's operation and reduce the pain at the injection site.

[0083] Effect Example 2 Cytotoxicity Detection

[0084] Mouse fibroblast L929 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences and cultured in MEM medium containing 10% serum and 1% penicillin-streptomycin.

[0085] Preparation of the sample to be tested: Using complete culture medium as diluent, dilute the sample prepared in the above Examples 1 to 4, Comparative Examples 1 to 2 or Comparative Example 5 5 times (by volume), shake on a shaker for 24 hours (37° C., 150 rpm), and take 100 μL as the sample to be tested.

[0086] Mouse fibroblast L929 cells were cultured in MEM medium containing 10% serum and 1% penicillin-streptomycin and incubated at 37°C and 5% CO2 until the cell growth state stabilized. 4 / well density was inoculated in a 96-well cell culture plate. After 24 hours, the culture plate was rinsed once with PBS, and the sample to be tested was added. Three parallels were set for each sample to be tested. After 24 hours of culture, the culture medium in the 96-well plate was discarded, and it was rinsed once with PBS. 50 μL of MTT test solution (MTT test solution with a concentration of 1 mg / mL prepared with blank culture medium) was added to each well. After incubation in a cell culture incubator for 2 hours, the culture medium was discarded, and 100 μL of isopropanol was added to each well, shaken for 2 minutes, and the absorbance at 570 nm was measured. The cell survival rate was calculated based on the test results, and the results are shown in Table 3.

[0087] Table 3

[0088] serial number Cell viability Example 1 98.94±5.93% Example 2 91.00±18.60% Example 3 95.10±10.01% Example 4 97.87±7.25% Comparative Example 1 73.06±2.33% Comparative Example 2 43.22±4.78% Comparative Example 5 56.72±4.65%

[0089] According to the comparison of the results of Comparative Example 1 and Comparative Example 5, free lactic acid has a greater cytotoxicity, and the cytotoxicity of PEG-PLA copolymer is significantly reduced compared with free lactic acid, but the degree of reduction is limited, and the PEG-PLA copolymer still has a certain cytotoxicity. In the research and development process of this application, it was creatively discovered that after the PEG-PLA copolymer and sodium hyaluronate were used in combination, the cytotoxicity was significantly reduced, and it was lower than the cytotoxicity when the PEG-PLA copolymer (Comparative Example 1) or sodium hyaluronate (Comparative Example 2) was used alone, which significantly improved the safety of the sample.

[0090] Effect Example 3 Antioxidant Capacity Determination

[0091] (1) Total antioxidant capacity determination method

[0092] The Prussian blue method was used. 1 mL of the composite solution of the PEG-PLA copolymer prepared in Example 1 or Comparative Examples 3 to 4 was taken respectively, 2.5 mL of a phosphate buffer solution with a pH of 6.6 and 2.5 mL of a 1% potassium ferricyanide (K3Fe(CN)6) solution were added, the mixture was placed at 50°C for 20 min, 2.5 mL of a 10% trichloroacetic acid solution was added and mixed, 2.5 mL of the mixture was taken, 2.5 mL of distilled water and 2.5 mL of 0.1% ferric chloride were added, the mixture was mixed, and the mixture was allowed to stand for 10 min. The absorbance was measured at 700 nm, and the total antioxidant capacity was calculated. The results are shown in Table 4.

[0093] (2) Pyrogallol auto-oxidation method

[0094] Take 1.8 mL of Tris-HCl-EDTA buffer with a pH value of 8.2, add 1.0 mL of the composite solution of PEG-PLA copolymer prepared in Example 1 or Comparative Examples 3 to 4 to the experimental group, and add an equal amount of purified water to the control group, and place in a water bath at 25°C for 10 min, add 0.1 mL of 10 mmol / L pyrogallol hydrochloric acid solution preheated at 25°C, mix quickly, scan at 320 nm for 4 minutes after 0.5 min, and measure the absorbance value every 0.5 min. The slope of the absorbance-time curve is used as the sample oxidation rate to calculate O 2- Inhibition rate: 3 parallels were set for each sample to be tested, and the results were averaged. The results are shown in Table 4.

[0095] O 2- Inhibition rate = (K0-K 样 ) / K0×100%;

[0096] K0: slope of control tube;

[0097] K 样 : Sample tube slope.

[0098] (3) Phenomenalanine-Fe 2+ Oxidation method

[0099] Pipette 1.5mL 5mmol / L o-phenanthroline application solution, add 4mL pH7.4 sodium phosphate buffer, and mix thoroughly. Then add 1mL 7.5mmol / L FeSO4 solution and mix immediately. Add 1mL sample solution of a certain concentration and mix immediately. Add 1.5mL double distilled water to make up the volume. Finally, add 1.0mL 1% H2O2 solution, replace H2O2 solution with double distilled water as a blank control, and mix gently. Keep warm at 37℃ for 90min. Measure the absorbance at 536nm. Calculate the hydroxyl radical scavenging rate. The results are shown in Table 4; the hydroxyl radical scavenging rate calculation formula is:

[0100]

[0101] A Dosing: Add sample (antioxidant) and H2O2;

[0102] A damage: adding H2O2 without adding antioxidants;

[0103] A No loss: neither is added.

[0104] (4) DPPH scavenging activity assay method

[0105] Add 4 mL of pH 6.86 standard mixed phosphate buffer, 4 mL of 2×10 4mol / LDPPH solution (prepared with 95% ethanol) was shaken. Then 1 mL of the test solution was added, and the volume was supplemented to 10.00 mL with distilled water, and the mixture was fully mixed. After 10 minutes, the absorbance was measured at 520 nm using 95% ethanol as a reference, and the DPPH clearance rate was calculated. The results are shown in Table 4.

[0106] DPPH clearance rate (%) = (1-(As-A single) / (A0-A double)) × 100%

[0107] As: absorbance of DPPH solution after adding sample;

[0108] A: No DPPH is added, only the absorbance of the solution with sample and water is added;

[0109] A0: absorbance of the solution with no sample but only DPPH and water;

[0110] A double: absorbance of the solution with only water added but no DPPH or sample.

[0111] Table 4

[0112] serial number Total Antioxidant Power Hydroxyl radical <![CDATA[O 2- Inhibition rate]]> DPPH Example 1 109.39%±1.47% 34.82%±4.80% 55.17%±4.09% 5.52%±0.69% Comparative Example 3 117.44%±4.27% 52.68%±7.83% 9.82%±2.31% 7.56%±0.17% Comparative Example 4 <![CDATA[100% & ]]> 38.35%±12.40% 22.99%±7.48% -1.78%±1.44%

[0113] The results show that in the four antioxidant capacity tests, the copolymer showed good antioxidant capacity in the three tests of total antioxidant capacity, scavenging hydroxyl free radicals and scavenging DPPH; and after combining with hyaluronic acid, the overall effect was good, and in the test of anti-superoxide anion, it showed the best antioxidant capacity. Comprehensive evaluation of the four antioxidant capacities showed that the composite solution had the best value.

[0114] Effect Example 4 Verification of the protective effect of PEG-PLA copolymer on sodium hyaluronate

[0115] The samples prepared in the above-mentioned Example 1 and Comparative Example 4 were placed under ultraviolet irradiation, the intrinsic viscosity of the samples was tested before and after irradiation, and the reduction ratio of the intrinsic viscosity was calculated. The results are shown in Table 5.

[0116] The intrinsic viscosity is measured according to the second method of Ubbelohde capillary viscometer measurement in the viscosity determination method of Pharmacopoeia 2020 edition 0633; the test conditions are Ubbelohde viscometer (inner diameter 0.53mm), temperature 25°C, solvent 0.2mol / L sodium chloride; the equipment used in the test is Ubbelohde viscometer (PXWSN-4A, Shanghai Pingxuan Scientific Instruments).

[0117] Table 5

[0118] serial number Before UV irradiation (mL / g) After UV irradiation (mL / g) Intrinsic viscosity reduction ratio Example 1 1.95±0.06 0.74±0.22 61.99±0.99% Comparative Example 4 2.41±0.19 1.21±0.98 49.63±2.00%

[0119] From the results of hyaluronic acid oxidation degradation, it can be seen that the sample prepared in Comparative Example 4 (without the addition of PEG-PLA copolymer) has a higher decrease rate of intrinsic viscosity after ultraviolet irradiation, while the addition of PEG-PLA copolymer in Example 1 reduces the decrease rate of intrinsic viscosity of the system. It can be seen that PEG-PLA copolymer has a protective effect on sodium hyaluronate and slows down the oxidative degradation rate of sodium hyaluronate after ultraviolet stimulation.

[0120] Effect Example 5 Mouse Skin Aging Test

[0121] 1. Experimental Animal Preparation

[0122] Non-model animal preparation:

[0123] A total of 24 KM mice (6 weeks old, 18-22 g, half male and half female) were used.

[0124] Animal model preparation:

[0125] Normal mice were injected with normal saline subcutaneously once a day, and model mice were injected with D-galactose (1 g / kg) subcutaneously once a day for 6 consecutive weeks to establish a subacute skin aging mouse model.

[0126] Criteria for successful modeling: The lipofuscin content in the modeling group was significantly different from that in the saline group.

[0127] 2. Experimental grouping and drug administration were carried out as follows.

[0128] The D-galactose solution injected into the model group was prepared as follows: D-galactose was dissolved in physiological saline to a 100 mg / mL sample.

[0129] The blank group, model group and experimental group were administrated according to the method in Table 6, and four injection points were selected for each mouse.

[0130] Table 6

[0131]

[0132] 3. Biochemical and pathological testing of samples

[0133] 3.1 Determination of biochemical indexes of mouse skin tissue

[0134] After the experiment, the back skin of mice in each group was taken, and the contents of lipofuscin (LF), hydroxyproline (HYP), and hyaluronic acid (HA) in the skin tissue were detected using a detection kit.

[0135] 3.1.1 Lipofuscin (LF) content in mouse skin tissue

[0136] The lipofuscin content in the skin tissue of the above groups was tested, and the results are shown in Figure 3 The results of lipofuscin (LF) content showed that there was a moderately significant difference in lipofuscin content in the skin tissue of the mice in the model group compared with the blank group ( △△ P < 0.005), it can be judged that under the drug administration conditions of this experiment, the subacute skin aging mouse model was successfully established. The lipofuscin content in the skin tissue of the mice in the model group was 11.36 ± 1.38 ng / mL; the lipofuscin content in the skin tissue of the mice in the experimental group 1 was 8.79 ± 0.37 ng / mL, which was extremely significantly different from the model group. *** P<0.001; the lipofuscin content in the skin tissue of mice in the experimental group 2 was 9.63±0.33ng / mL, which was significantly different from that in the model group. * P<0.01.

[0137] 3.1.2 Hydroxyproline (HYP) content in mouse skin tissue

[0138] The hydroxyproline content in the skin tissues of the above groups was tested, and the results are shown in Figure 4 The results of hydroxyproline (HYP) content showed that the HYP content in the skin tissue of the model group was 135.43±9.46μg / mL, and the HYP content in the skin tissue of the experimental group 1 was 163.24±18.64μg / mL, which was significantly different from the model group (P<0.01).

[0139] 3.1.3 Hyaluronic acid (HA) content in mouse skin tissue

[0140] The hyaluronic acid content in the skin tissue of each group was tested. The results are shown in Figure 5 . The results of hyaluronic acid (HA) content showed that the HA content in the skin tissue of the model group was 141.76±10.32pg / mL. The HA content in the skin tissue of the experimental group 1 was 161.67±10.89pg / mL, which was significantly different from that of the model group (P<0.01); the HA content in the skin tissue of the experimental group 2 was 163.58±6.49pg / mL, which was moderately significantly different from that of the model group (P<0.005).

[0141] Finally, it should be noted that in this application, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements that are not explicitly listed, or also includes elements that are inherent to such process, method, article or apparatus.

[0142] Although the present application has been disclosed above through the description of the specific embodiments of the present application, it should be understood that those skilled in the art can design various modifications, improvements or equivalents to the present application within the spirit and scope of the attached scheme. These modifications, improvements or equivalents should also be considered to be included in the scope of protection claimed in the present application.

Claims

1. A composite solution of PEG-PLA copolymer, characterized in that: The composite solution of the PEG-PLA copolymer comprises the following components in parts by weight: 2 to 15 parts of the PEG-PLA copolymer and 0.05 to 0.8 parts of hyaluronate; preferably, the composite solution of the PEG-PLA copolymer comprises a buffer solution.

2. The composite solution of PEG-PLA copolymer according to claim 1, characterized in that The composite solution of the PEG-PLA copolymer satisfies at least one of the following conditions (1) to (4): (1) The weight proportion of the PEG-PLA copolymer is 2 to 12 parts, preferably 2 to 10 parts, and more preferably 2 to 6 parts; (2) The weight proportion of the hyaluronate is 0.05 to 0.6 parts, preferably 0.1 to 0.5 parts; (3) The pH value of the composite solution of the PEG-PLA copolymer is 4 to 7.5, preferably 5 to 7, and more preferably 5.5 to 6.5; (4) The osmotic pressure of the composite solution of the PEG-PLA copolymer is 200 mOsmol / kg to 400 mOsmol / kg, preferably 250 mOsmol / kg to 350 mOsmol / kg.

3. The composite solution of PEG-PLA copolymer according to claim 1, characterized in that The composite solution of the PEG-PLA copolymer comprises the PEG-PLA copolymer, the hyaluronate and the buffer; wherein the mass percentage of the PEG-PLA copolymer in the composite solution of the PEG-PLA copolymer is 2% to 15%, preferably 2% to 12%, more preferably 2% to 10%, and further more preferably 2% to 6%; the mass percentage of the hyaluronate in the composite solution of the PEG-PLA copolymer is 0.05% to 0.8%, preferably 0.05% to 0.6%, and more preferably 0.1% to 0.5%.

4. The composite solution of PEG-PLA copolymer according to any one of claims 1 to 3, characterized in that: The composite solution of the PEG-PLA copolymer satisfies at least one of the following conditions (1) to (6): (1) The hyaluronate is at least one selected from the group consisting of sodium hyaluronate, potassium hyaluronate, calcium hyaluronate and zinc hyaluronate, preferably sodium hyaluronate; (2) The weight average molecular weight of the hyaluronate is 8 WDa to 150 WDa, preferably 100 WDa to 140 WDa; (3) The buffer is selected from any one of phosphate buffer, citrate buffer, sodium chloride solution or a combination thereof; (4) The pH value of the buffer solution is 7 to 12, preferably 7 to 9; (5) The osmotic pressure of the buffer solution is 120 to 410 mOsmol / kg, preferably 220 to 400 mOsmol / kg; (6) The preparation method of the PEG-PLA copolymer comprises the following steps: preparing the PEG-PLA copolymer by polymerization reaction of a single-terminal hydroxyl polyethylene glycol compound and lactide.

5. The composite solution of PEG-PLA copolymer as claimed in claim 4, characterized in that The preparation method of the PEG-PLA copolymer satisfies at least one of the following conditions (1) to (9): (1) The mass ratio of the single-end hydroxyl polyethylene glycol compound to the lactide is (3.5-49):1, preferably (9-49):1, preferably (9-20):1; (2) The single-terminal hydroxyl polyethylene glycol compound is polyethylene glycol monoalkyl ether, preferably polyethylene glycol mono-C 1-6 Alkyl ether, more preferably polyethylene glycol monomethyl ether; (3) The weight average molecular weight of the single-end hydroxyl polyethylene glycol compound is 1000-11000 Da, preferably 4000-11000 Da, more preferably 5000-10000 Da; (4) The lactide is at least one selected from L-lactide, D-lactide and D,L-lactide; (5) The polymerization reaction is carried out under the action of a catalyst; preferably, the catalyst is a tin-based metal catalyst, more preferably selected from at least one of dibutyltin diacetate, dibutyltin dibenzoate, tri-n-butyltin methoxy, dibutyltin dilaurate, stannous octoate, stannous octoate and stannous isooctanoate; preferably, the mass percentage of the catalyst in the polymerization reaction system is 0.01% to 0.03%, more preferably 0.02% to 0.03%; (6) The polymerization reaction is carried out under anaerobic conditions; (7) The polymerization reaction temperature is 70-150°C, preferably 90-135°C, more preferably 100-130°C; (8) The polymerization reaction time is 8 to 20 hours, preferably 11 to 16 hours; (9) The polymerization reaction further includes purification and / or drying operations.

6. The composite solution of PEG-PLA copolymer as claimed in claim 5, characterized in that The preparation method of the PEG-PLA copolymer satisfies at least one of the following conditions (1) to (3): (1) The purification comprises the following steps: the material after the polymerization reaction is mixed with a good solvent once, dissolved and then mixed with a poor solvent for a second time, crystallized, and precipitated; (2) The drying temperature is 30-40°C, preferably 33-37°C; (3) The drying time is 20 to 48 hours.

7. The composite solution of PEG-PLA copolymer as claimed in claim 6, characterized in that The purification satisfies at least one of the following conditions (1) to (6): (1) The good solvent is a halogenated alkane, preferably selected from dichloromethane and / or chloroform; (2) The mass volume ratio of the material after the polymerization reaction to the good solvent is 0.8 to 3 g / mL, preferably 1 to 2 g / mL; (3) After the primary mixing, the operation of adsorption is further included; preferably, the adsorbent used in the adsorption is selected from activated carbon; preferably, the mass volume ratio of the adsorbent used in the adsorption to the adsorbed system is 75-150 g / L; more preferably, after the adsorption operation, the operation of filtering and removing the adsorbent is further included; (4) The poor solvent is an ether solvent, preferably isopropyl ether and / or diethyl ether; (5) The volume ratio of the good solvent to the poor solvent is 1:(4-10), preferably 1:(6-10); (6) The method for collecting the precipitate includes filtration and / or centrifugation.

8. A method for preparing a composite solution of a PEG-PLA copolymer as claimed in any one of claims 1 to 7, characterized in that: The method comprises the following steps: uniformly mixing the components in the composite solution of the PEG-PLA copolymer; Preferably, the mixing operation further includes a sterilization operation; More preferably, the sterilization method comprises filtration and / or irradiation sterilization.

9. A composite solution of PEG-PLA copolymer, characterized in that: Prepared by the preparation method as claimed in claim 8.

10. Use of the composite solution of the PEG-PLA copolymer according to any one of claims 1 to 7 or the composite solution of the PEG-PLA copolymer according to claim 9 as a raw material in the preparation of an injectable preparation in the field of medical beauty; Preferably, the injectable preparation is an injection solution or a lyophilized powder injection.

Citation Information

Patent Citations

  • Polyethylene glycol monomethyl ether polylactic acid copolymer as well as preparation method and application thereof

    CN116102721A

Cited By

  • Skin implant and preparation method thereof

    CN121796338A